Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Multiple Myeloma 2Melanoma 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1Advanced Malignant Solid Neoplasm 1

Interventions

aldesleukin 65Cyclophosphamide 45fludarabine phosphate 30fludarabine 27Interleukin-2 24incomplete Freund's adjuvant 22Ipilimumab 17Specimen Handling 14MART-1 Antigen 14CTLA-4 Antigen 14sargramostim 13Magnetic Resonance Spectroscopy 13Biopsy 13montanide ISA 51 11Nivolumab 11Filgrastim 11Sorafenib 10Interferon-alpha 9trametinib 8pembrolizumab 8dabrafenib 8Sirolimus 7Bevacizumab 7temsirolimus 6Temozolomide 6Taxes 5Paclitaxel 5Introns 5Gene Expression Profiling 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Melanoma × dinaciclib × Clear all
NCT00937937 2026-05-29

Dinaciclib in Treating Patients With Stage IV Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled 14 charts
Dermatologic

Melanoma

NCT01026324 2017-04-04

Dinaciclib in Treating Patients With Stage III-IV Melanoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
12 enrolled 9 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡